Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANABNASDAQ:INMBNASDAQ:ORICNASDAQ:XERS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$23.32-0.4%$20.50$12.21▼$41.31$685.14M-0.26872,353 shs378,901 shsINMBINmune Bio$7.70-2.8%$7.52$4.32▼$10.50$176.98M1.55286,631 shs592,485 shsORICORIC Pharmaceuticals$9.63-0.4%$6.04$3.90▼$14.67$684.58M1.49773,381 shs714,123 shsXERSXeris Biopharma$4.35-1.6%$4.54$2.03▼$6.07$680.28M0.711.98 million shs1.78 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio-0.81%+10.74%+14.08%+39.93%-2.86%INMBINmune Bio-2.10%+7.76%-1.74%-0.38%-9.49%ORICORIC Pharmaceuticals+2.98%+5.57%+82.11%+24.13%+22.41%XERSXeris Biopharma+0.91%-0.90%-9.80%-8.30%+97.32%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANABAnaptysBio1.7841 of 5 stars3.40.00.00.02.71.70.6INMBINmune Bio2.0771 of 5 stars3.60.00.00.03.21.70.6ORICORIC Pharmaceuticals3.9039 of 5 stars3.50.00.04.32.72.50.6XERSXeris Biopharma3.9134 of 5 stars3.42.00.04.21.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.80Moderate Buy$42.3881.71% UpsideINMBINmune Bio 3.17Buy$22.80188.75% UpsideORICORIC Pharmaceuticals 3.00Buy$19.17103.04% UpsideXERSXeris Biopharma 2.83Moderate Buy$6.2542.53% UpsideCurrent Analyst Ratings BreakdownLatest INMB, ORIC, XERS, and ANAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2025ANABAnaptysBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$22.00 ➝ $38.005/29/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$40.005/29/2025ORICORIC PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$20.005/28/2025ANABAnaptysBioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $90.005/9/2025XERSXeris BiopharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$6.00 ➝ $7.005/6/2025ANABAnaptysBioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$52.00 ➝ $54.005/6/2025ORICORIC PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$15.00 ➝ $12.005/6/2025ORICORIC PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/5/2025ORICORIC PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $21.005/1/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$40.00 ➝ $40.003/26/2025ANABAnaptysBioJohnson RiceSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$111.87M6.12N/AN/A$3.32 per share7.02INMBINmune Bio$50K3,629.63N/AN/A$2.07 per share3.81ORICORIC PharmaceuticalsN/AN/AN/AN/A$3.42 per shareN/AXERSXeris Biopharma$222.55M3.08N/AN/A($0.05) per share-87.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$163.62M-$4.85N/AN/AN/A-289.75%-287.94%-37.25%8/4/2025 (Estimated)INMBINmune Bio-$30.01M-$1.93N/AN/AN/AN/A-117.48%-78.96%7/30/2025 (Estimated)ORICORIC Pharmaceuticals-$100.70M-$1.87N/AN/AN/AN/A-44.54%-40.72%8/11/2025 (Estimated)XERSXeris Biopharma-$62.26M-$0.30N/AN/AN/A-33.69%N/A-17.38%8/6/2025 (Estimated)Latest INMB, ORIC, XERS, and ANAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025INMBINmune Bio-$0.43-$0.43N/A-$0.43N/A$0.05 million5/8/2025Q1 2025XERSXeris Biopharma-$0.07-$0.06+$0.01-$0.06$57.61 million$57.80 million5/5/2025Q1 2025ANABAnaptysBio-$1.30-$1.28+$0.02-$1.28$15.27 million$27.77 million5/5/2025Q1 2025ORICORIC Pharmaceuticals-$0.51-$0.42+$0.09-$0.42N/AN/A3/27/2025Q4 2024INMBINmune Bio-$0.54-$0.40+$0.14-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/AORICORIC PharmaceuticalsN/AN/AN/AN/AN/AXERSXeris BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A10.2310.23INMBINmune BioN/A2.592.59ORICORIC PharmaceuticalsN/A10.5613.15XERSXeris BiopharmaN/A1.791.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/AINMBINmune Bio12.72%ORICORIC Pharmaceuticals95.05%XERSXeris Biopharma42.75%Insider OwnershipCompanyInsider OwnershipANABAnaptysBio33.50%INMBINmune Bio35.20%ORICORIC Pharmaceuticals6.82%XERSXeris Biopharma6.47%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10029.38 million20.17 millionOptionableINMBINmune Bio1022.98 million14.37 millionOptionableORICORIC Pharmaceuticals8071.09 million67.09 millionOptionableXERSXeris Biopharma290156.39 million142.28 millionOptionableINMB, ORIC, XERS, and ANAB HeadlinesRecent News About These CompaniesLeerink Partnrs Estimates Xeris Biopharma FY2025 EarningsJune 9, 2025 | marketbeat.comQ3 EPS Estimates for Xeris Biopharma Cut by Leerink PartnrsJune 8, 2025 | americanbankingnews.comLeerink Partnrs Cuts Earnings Estimates for Xeris BiopharmaJune 6, 2025 | marketbeat.comXeris Biopharma touts ambitious growth plan, promising hypothyroidism drugJune 4, 2025 | chicagobusiness.comMackenzie Financial Corp Buys 106,153 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)June 4, 2025 | marketbeat.comXeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor DayJune 3, 2025 | finance.yahoo.comXeris Biopharma (NASDAQ:XERS) Shares Down 5.5% - Here's What HappenedJune 3, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Consensus Rating of "Moderate Buy" from AnalystsJune 3, 2025 | americanbankingnews.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from AnalystsJune 3, 2025 | marketbeat.comNuveen Asset Management LLC Acquires 228,380 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)June 1, 2025 | marketbeat.comMillennium Management LLC Raises Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)May 29, 2025 | marketbeat.comBNP Paribas Financial Markets Acquires Shares of 100,012 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)May 28, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Rating Lowered to Hold at Wall Street ZenMay 24, 2025 | marketbeat.comXeris Announces Details for Analyst & Investor DayMay 20, 2025 | businesswire.comStonepine Capital Management LLC Makes New $618,000 Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)May 20, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by D. E. Shaw & Co. Inc.May 20, 2025 | marketbeat.comLeerink Partnrs Weighs in on Xeris Biopharma Q2 EarningsMay 17, 2025 | marketbeat.comParkman Healthcare Partners LLC Increases Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)May 16, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Lowers Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)May 13, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in NowMay 12, 2025 | msn.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2025 Earnings Call TranscriptMay 10, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingIn a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback StockBy Leo Miller | June 9, 2025View In a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback StockAdvance Auto Parts Jumps on Surprise Earnings BeatBy Chris Markoch | May 23, 2025View Advance Auto Parts Jumps on Surprise Earnings BeatINMB, ORIC, XERS, and ANAB Company DescriptionsAnaptysBio NASDAQ:ANAB$23.32 -0.09 (-0.38%) Closing price 04:00 PM EasternExtended Trading$23.32 +0.00 (+0.02%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.INmune Bio NASDAQ:INMB$7.70 -0.22 (-2.78%) Closing price 04:00 PM EasternExtended Trading$7.62 -0.08 (-1.04%) As of 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.ORIC Pharmaceuticals NASDAQ:ORIC$9.63 -0.04 (-0.41%) Closing price 04:00 PM EasternExtended Trading$9.62 -0.01 (-0.05%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Xeris Biopharma NASDAQ:XERS$4.35 -0.07 (-1.58%) Closing price 04:00 PM EasternExtended Trading$4.28 -0.07 (-1.59%) As of 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
